

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (withdrawn-currently amended): ~~Use of one or more synthetic CRH-R1 antagonists and/or CRH-R2 agonists~~ A method for the treatment of an inflammatory disease or condition associated to activation, deactivation, differentiation and apoptosis of macrophages comprising administering an effective amount of one or more synthetic CRH-R1 antagonists and/or CRH-R2 agonists to a patient in need thereof.
2. (withdrawn-currently amended): ~~Use~~ The method according to claim 1, wherein the one or more synthetic CRH-R1 antagonists and/or CRH-R2 agonists comprises antalarmin.
- 3 (withdrawn-currently amended): ~~Use~~ The method according to claim 1, wherein the inflammatory disease or condition is chronic inflammatory bowel disease, idiopathic inflammatory disorder, inflammatory disorders of connective tissues, inflammatory demyelinating polyneuropathies, inflammatory myopathies, inflammatory diseases of joints including bursitis, the fibromyalgia syndrome and inflammatory diseases of upper gastrointestinal tract.
4. (currently amended): ~~Pharmaceutical~~ A pharmaceutical composition comprising one or more synthetic CRH-R1 antagonists and /or CRH-R2 agonists.
5. (currently amended): ~~Pharmaceutical~~ The pharmaceutical composition according to claim 4, wherein the composition is formulated for local or systemic administration.

6. (currently amended): ~~Pharmaceutical~~ The pharmaceutical composition according to claim 4, wherein the composition further comprises usual exhibients such as diluents, fillers, binders, disintegrants, lubricants, conserving agents, flavourings and colourings.
7. (currently amended): ~~Pharmaceutical~~ The pharmaceutical composition according to claim 4, wherein the formulation is formulated for oral, parenteral or intradermal administration.
8. (currently amended): ~~Pharmaceutical~~ The pharmaceutical composition according to claim 4, wherein the composition is formulated as an injection liquid.
9. (currently amended): ~~Pharmaceutical~~ The pharmaceutical composition according to claim 4, wherein the one or more synthetic CRH-R1 antagonist and/or CRH-R2 agonist comprises antalarmin.
10. (currently amended): ~~Pharmaceutical~~ The pharmaceutical composition according to claim 4, wherein the one of more synthetic CRH-R1 antagonist and/or CRH-R2 agonist is antalarmin.
11. (withdrawn - currently amended): ~~Use of one~~ A process ~~or more synthetic CRH-R1 antagonists and/or CRH-R2 agonists for the manufacture of a pharmaceutical composition for the treatment of an inflammatory disease or condition associated to activation, deactivation, differentiation and apoptosis of macrophages comprising combining one or more synthetic CRH-R1 antagonists and/or CRH-R2 agonist and a pharmaceutical carrier.~~
12. (withdrawn-currently amended): ~~Use~~ The process according to claim 11, wherein the inflammatory disease or condition is chronic inflammatory bowel disease, idiopathic inflammatory disorder, inflammatory disorders of connective tissues, inflammatory demyelinating polyneuropathies, inflammatory myopathies, inflammatory diseases of

joints including bursitis, the fibromyalgia syndrome and inflammatory diseases of upper gastrointestinal tract.

13. (currently amended): A kit ~~intended~~ for the treatment of an inflammatory disease or condition comprising one or more CRH-R1 antagonists and /or CRH-R2 agonists comprised in one of more individual pharmaceutical compositions.

14. (currently amended): ~~Kit~~ The kit according to claim 13, wherein the one or more CRH-R1 antagonists and/or CRH-R2 agonists comprises antalarmin.